[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012016460A2 - diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. - Google Patents

diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.

Info

Publication number
BR112012016460A2
BR112012016460A2 BR112012016460A BR112012016460A BR112012016460A2 BR 112012016460 A2 BR112012016460 A2 BR 112012016460A2 BR 112012016460 A BR112012016460 A BR 112012016460A BR 112012016460 A BR112012016460 A BR 112012016460A BR 112012016460 A2 BR112012016460 A2 BR 112012016460A2
Authority
BR
Brazil
Prior art keywords
diazoxide
pharmaceutically acceptable
acceptable salt
nervous system
central nervous
Prior art date
Application number
BR112012016460A
Other languages
English (en)
Inventor
Zamorano Andreza
Mahy Gehenne Josettenicole
Francisco Espinosa Parrilla Juan
Rodríguez Allué Manuel
Pugliese Marco
Virgili Treserres Noemí
Mancera Aroca Pilar
Original Assignee
Neurotec Pharma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotec Pharma S L filed Critical Neurotec Pharma S L
Publication of BR112012016460A2 publication Critical patent/BR112012016460A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. a invenção se refere à utilização de diazóxido ou de um sal farmaceuticamente aceitável deste em doses baixas para tratar uma doença desmielinizante autoimune do sistema nervoso central cns selecionada a partir de esclerose múltipla (ms), síndrome clínica isolada (cis), esclerose múltipla tumefativa (do tipo tumor), esclerose múltipla aguda de marburg, esclerose concêntrica de balós, encefalomielite disseminada (adem), encefalite pós-vacinal (pve), encefalomielite pós-infecciosa (pie) e neuromielite óptica (nmo).
BR112012016460A 2010-01-04 2011-01-04 diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. BR112012016460A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10150027A EP2343075A1 (en) 2010-01-04 2010-01-04 Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
PCT/EP2011/050049 WO2011080344A1 (en) 2010-01-04 2011-01-04 Diazoxide for use in the treatment of a central nervous system (cns) autoimmune demyelinating disease

Publications (1)

Publication Number Publication Date
BR112012016460A2 true BR112012016460A2 (pt) 2019-09-24

Family

ID=42027816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016460A BR112012016460A2 (pt) 2010-01-04 2011-01-04 diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.

Country Status (12)

Country Link
US (1) US20130039905A1 (pt)
EP (2) EP2343075A1 (pt)
JP (1) JP2013527132A (pt)
KR (1) KR20120104422A (pt)
CN (1) CN102770142A (pt)
AU (1) AU2011203402A1 (pt)
BR (1) BR112012016460A2 (pt)
CA (1) CA2786155A1 (pt)
MX (1) MX2012007778A (pt)
RU (1) RU2012133528A (pt)
WO (1) WO2011080344A1 (pt)
ZA (1) ZA201205036B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
PL2665471T3 (pl) 2011-01-19 2018-06-29 Pathologica, Llc. Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
DK2943189T3 (da) 2013-01-08 2021-04-06 Pathologica Llc Mitoguazon til behandling af progressiv multipel sklerose
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
EP2805730A1 (en) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3831369A1 (en) * 2019-12-03 2021-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Squalene for the treatment of demyelinating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254871A1 (en) 2004-06-23 2007-11-01 Neurotec Pharma, S.L. Compounds for the Treatment of Inflammation of the Central Nervous System
EP2170341A4 (en) * 2007-07-02 2010-12-01 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND ITS USES

Also Published As

Publication number Publication date
RU2012133528A (ru) 2014-02-20
WO2011080344A1 (en) 2011-07-07
EP2343075A1 (en) 2011-07-13
CA2786155A1 (en) 2011-07-07
US20130039905A1 (en) 2013-02-14
MX2012007778A (es) 2012-09-12
EP2521552A1 (en) 2012-11-14
CN102770142A (zh) 2012-11-07
ZA201205036B (en) 2013-02-27
JP2013527132A (ja) 2013-06-27
KR20120104422A (ko) 2012-09-20
AU2011203402A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
BR112012016460A2 (pt) diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
SG10201803778PA (en) Treatment for rheumatoid arthritis
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
MX355482B (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
NZ771184A (en) Dosage regimen for madcam antagonists
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CR20120084A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
UA115250C2 (uk) Фармацевтичні комбінації
EA201270206A1 (ru) Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применение
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.